{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:19:46Z","timestamp":1793074786004,"version":"4.5.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1681\/asn.2017070818","type":"journal-article","created":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T09:44:12Z","timestamp":1513244652000},"page":"591-605","source":"Crossref","is-referenced-by-count":296,"title":["A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection"],"prefix":"10.1681","volume":"29","clinical-trial-number":[{"clinical-trial-number":"nct02201576","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01873157","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Farsad","family":"Eskandary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Regele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Kozakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wahrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis G.","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmuth","family":"Haslacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Kaltenecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Bernadette","family":"Aretin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Oberbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Posch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Staudenherz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammon","family":"Handisurya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Reeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip F.","family":"Halloran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg A.","family":"B\u00f6hmig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,12,14]]},"reference":[{"key":"B1-20230120","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence.","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant"},{"key":"B2-20230120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrneph.2013.18","article-title":"Transplantation: Donor-specific HLA antibodies and renal allograft failure.","volume":"9","author":"Loupy","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"B3-20230120","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.","volume":"14","author":"Haas","year":"2014","journal-title":"Am J Transplant"},{"key":"B4-20230120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ajt.14107","article-title":"The Banff 2015 kidney meeting report: Current challenges in rejection classification and prospects for adopting molecular pathology.","volume":"17","author":"Loupy","year":"2017","journal-title":"Am J Transplant"},{"key":"B5-20230120","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nrneph.2016.85","article-title":"Molecular assessment of disease states in kidney transplant biopsy samples.","volume":"12","author":"Halloran","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B6-20230120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00007890-200107150-00016","article-title":"Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection.","volume":"72","author":"Theruvath","year":"2001","journal-title":"Transplantation"},{"key":"B7-20230120","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1432-2277.2012.01544.x","article-title":"IVIG and rituximab for treatment of chronic antibody-mediated rejection: A prospective study in paediatric renal transplantation with a 2-year follow-up.","volume":"25","author":"Billing","year":"2012","journal-title":"Transpl Int"},{"key":"B8-20230120","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: A pilot randomized controlled trial.","volume":"17","author":"Kulkarni","year":"2017","journal-title":"Am J Transplant"},{"key":"B9-20230120","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-IL-6 receptor monoclonal) as a potential treatment for chronic antibody mediated rejection and transplant glomerulopathy in HLA sensitized renal allograft recipients.","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant"},{"key":"B10-20230120","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy.","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B11-20230120","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/ki.2011.502","article-title":"Proteasome inhibitor-based therapy for antibody-mediated rejection.","volume":"81","author":"Walsh","year":"2012","journal-title":"Kidney Int"},{"key":"B12-20230120","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1089\/ars.2014.5892","article-title":"Review of bortezomib treatment of antibody-mediated rejection in renal transplantation.","volume":"21","author":"Ejaz","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"B13-20230120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-6143.2008.02461.x","article-title":"Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production.","volume":"9","author":"Perry","year":"2009","journal-title":"Am J Transplant"},{"key":"B14-20230120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-015-0529-1","article-title":"Proteasome inhibitors as experimental therapeutics of autoimmune diseases.","volume":"17","author":"Verbrugge","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B15-20230120","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"key":"B16-20230120","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/TP.0b013e3181a4b91b","article-title":"Abrogation of anti-HLA antibodies via proteasome inhibition.","volume":"87","author":"Trivedi","year":"2009","journal-title":"Transplantation"},{"key":"B17-20230120","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/TP.0b013e318218e901","article-title":"Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition.","volume":"91","author":"Walsh","year":"2011","journal-title":"Transplantation"},{"key":"B18-20230120","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/ndt\/gfr465","article-title":"Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.","volume":"27","author":"Waiser","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B19-20230120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/ajt.13050","article-title":"Prospective iterative trial of proteasome inhibitor-based desensitization.","volume":"15","author":"Woodle","year":"2015","journal-title":"Am J Transplant"},{"key":"B20-20230120","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/TP.0b013e318257acf6","article-title":"Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients.","volume":"94","author":"Schmidt","year":"2012","journal-title":"Transplantation"},{"key":"B21-20230120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1745-6215-15-107","article-title":"Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT study): Study protocol for a randomized controlled trial.","volume":"15","author":"Eskandary","year":"2014","journal-title":"Trials"},{"key":"B22-20230120","article-title":"Real time central assessment of kidney transplant indication biopsies by microarrays: The INTERCOMEX study [published online ahead of print April 27, 2010].","author":"Halloran","journal-title":"Am J Transplant"},{"key":"B23-20230120","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/ndt\/gfw027","article-title":"Deceased donor kidney transplantation across donor-specific antibody barriers: Predictors of antibody-mediated rejection.","volume":"31","author":"Schwaiger","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B24-20230120","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/ajt.13347","article-title":"Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am J Transplant"},{"key":"B25-20230120","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res"},{"key":"B26-20230120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.seminhematol.2012.04.005","article-title":"The proteasome in terminal plasma cell differentiation.","volume":"49","author":"Cenci","year":"2012","journal-title":"Semin Hematol"},{"key":"B27-20230120","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"B28-20230120","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/TP.0b013e3182081333","article-title":"The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo.","volume":"91","author":"Diwan","year":"2011","journal-title":"Transplantation"},{"key":"B29-20230120","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/01.TP.0000441091.47464.c6","article-title":"Complement component C3 activation: The leading cause of the prozone phenomenon affecting HLA antibody detection on single-antigen beads.","volume":"97","author":"Schwaiger","year":"2014","journal-title":"Transplantation"},{"key":"B30-20230120","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/TP.0000000000001195","article-title":"Diagnostic contribution of donor-specific antibody characteristics to uncover late silent antibody-mediated rejection-results of a cross-sectional screening study.","volume":"101","author":"Eskandary","year":"2017","journal-title":"Transplantation"},{"key":"B31-20230120","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1097\/TP.0b013e3181d9e1c0","article-title":"Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.","volume":"89","author":"Wahrmann","year":"2010","journal-title":"Transplantation"},{"key":"B32-20230120","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1600-6143.2009.02968.x","article-title":"Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies.","volume":"10","author":"Sberro-Soussan","year":"2010","journal-title":"Am J Transplant"},{"key":"B33-20230120","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.trim.2012.01.002","article-title":"Proteasome inhibition by bortezomib: Effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.","volume":"26","author":"Guthoff","year":"2012","journal-title":"Transpl Immunol"},{"key":"B34-20230120","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1681\/ASN.2016070727","article-title":"Humoral compensation after bortezomib treatment of allosensitized recipients.","volume":"28","author":"Kwun","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B35-20230120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study.","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"B36-20230120","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1681\/ASN.2017040443","article-title":"Targeting plasma cells with proteasome inhibitors: Principles from primates.","volume":"28","author":"Woodle","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B37-20230120","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/01.TP.0000442503.85766.91","article-title":"Late antibody-mediated rejection in renal allografts: Outcome after conventional and novel therapies.","volume":"97","author":"Gupta","year":"2014","journal-title":"Transplantation"},{"key":"B38-20230120","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/ctr.12535","article-title":"Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: A pilot study.","volume":"29","author":"Bachelet","year":"2015","journal-title":"Clin Transplant"},{"key":"B39-20230120","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study.","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"B40-20230120","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1399-0012.2005.00261.x","article-title":"Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation.","volume":"19","author":"Lederer","year":"2005","journal-title":"Clin Transplant"},{"key":"B41-20230120","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/TP.0b013e31817fdddb","article-title":"Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant.","volume":"86","author":"Opelz","year":"2008","journal-title":"Transplantation"},{"key":"B42-20230120","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/tri.12934","article-title":"Higher calcineurin inhibitor levels predict better kidney graft survival in patients with de novo donor-specific anti-HLA antibodies: A cohort study.","volume":"30","author":"B\u00e9land","year":"2017","journal-title":"Transpl Int"},{"key":"B43-20230120","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1111\/ajt.13341","article-title":"The synergistic effect of class II HLA epitope-mismatch and nonadherence on acute rejection and graft survival.","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am J Transplant"},{"key":"B44-20230120","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"B45-20230120","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1053\/j.ajkd.2014.09.006","article-title":"GFR decline as an end point in trials of CKD: A viewpoint from the FDA.","volume":"64","author":"Thompson","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B46-20230120","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/TP.0b013e3182692b70","article-title":"Identification and characterization of kidney transplants with good glomerular filtration rate at 1 year but subsequent progressive loss of renal function.","volume":"94","author":"Park","year":"2012","journal-title":"Transplantation"},{"key":"B47-20230120","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1681\/ASN.2015050524","article-title":"Relationship between eGFR decline and hard outcomes after kidney transplants.","volume":"27","author":"Clayton","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B48-20230120","doi-asserted-by":"crossref","first-page":"929","DOI":"10.7326\/0003-4819-141-12-200412210-00009","article-title":"Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease.","volume":"141","author":"Rule","year":"2004","journal-title":"Ann Intern Med"},{"key":"B49-20230120","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000445028","article-title":"Glomerular filtration rate and error calculation based on the slope-intercept method with chromium-51 ethylenediaminetetraacetic acid via a new clinical software: GFRcalc.","volume":"25","author":"Geist","year":"2016","journal-title":"Med Princ Pract"},{"key":"B51-20230120","doi-asserted-by":"crossref","first-page":"94197","DOI":"10.1172\/jci.insight.94197","volume":"2","author":"Reeve","year":"2017","journal-title":"JCI Insight"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201802000-00029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:30:10Z","timestamp":1786131010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201802000-00029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,14]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2017070818","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,14]]}}}